Glenmark Pharmaceuticals ltd

BSE: GLENMARK532296ISIN INE935A01035

Healthcare
Pharmaceuticals
BSE 500

BSE listing

Share price

₹2,380.00-34.50 (-1.43%)

as of 18 Sep 2026

52W high: ₹2,536.85
52W low: ₹1,794.00
Off 52W high: -6.18%
1M return: +5.54%
3M return: +7.50%
6M return: +9.12%
1Y return: +12.80%
20D avg volume: 20,483
50 DMA: ₹2,327.44
200 DMA: ₹2,179.69

Key ratios Consolidated

Market cap: ₹67,169 Cr
Current price: ₹2,380.00
52W high / low: ₹2,536.85 / ₹1,794.00
Face value: ₹1.00
P/E: 37.36
P/B: —
EPS (TTM): ₹63.71
Book value / share: —
ROE: —
ROCE: 16.20%
Operating margin: —
Net margin: —
Debt / equity: 0.00
Net debt: ₹-1,175 Cr
Interest cover: 10.51
Dividend yield: 0.21%
Dividend / share (TTM): ₹5.00
Payout: 7.85%
Cash conversion cycle: 99.9 days

About

In plain English

Glenmark is a global drugmaker that creates both affordable generic versions of existing medicines and its own innovative treatments, focusing on breathing problems (like asthma and allergies), skin conditions (such as eczema and acne), and cancer. For example, it sells RYALTRIS, a nasal spray for allergies and respiratory issues, now available in over 50 countries; GLIPIQ, a version of the blockbuster diabetes/weight-loss drug semaglutide that it launched in India; and a generic version of FloVent HFA, an asthma inhaler just approved in the US with exclusive marketing rights. Its customers range from patients and doctors to hospitals and other pharmaceutical companies – most notably AbbVie, which partnered with Glenmark to develop a groundbreaking multiple myeloma therapy. Glenmark makes money by selling these medicines across India, North America, Europe, and emerging markets like China and Brazil, and through out-licensing deals where it earns upfront payments, milestone fees, and royalties from partners.

AI-generated summary, written from the company's own filings and disclosures. Every figure elsewhere on this page comes from exchange data, not from a model. See our editorial standards. Generated 6 Jul 2026.

Financials

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	4,018	3,771	3,901	6,047	3,264	3,256	3,388	3,434	3,244	3,063	2,507	3,207
	65.76	189.08	44.47	200.63	26.44	11.69	31.13	39.42	31.49	773.16	45.41	1.70
	3,441	3,198	3,227	3,895	2,872	2,887	2,962	3,001	2,813	2,859	2,997	3,008
	601.07	731.20	775.29	722.50	732.47	794.78	746.37	774.36	685.77	754.31	657.50	915.75
	660.75	446.29	748.56	620.45	581.34	344.74	418.15	443.08	360.03	210.80	413.11	408.83
	934.70	887.44	841.40	1,086	762.75	736.57	788.49	786.57	710.44	700.96	753.04	732.88
	54.00	42.60	41.43	66.46	58.23	66.71	52.29	48.48	39.58	148.56	134.34	121.46
	173.17	147.91	154.45	141.20	129.93	125.20	122.74	120.28	117.79	151.34	147.07	141.45
	1,033	948.27	894.37	1,337	905.59	869.66	914.60	975.24	835.45	862.13	930.05	814.43
	643.39	761.17	718.34	2,353	418.81	380.79	456.33	472.57	462.33	977.61	-444.66	201.07
	0.00	-373.40	-184.34	-1,385	-323.23	-372.82	0.00	0.00	0.00	-446.78	-76.72	-325.42
	643.39	387.77	534.00	967.40	95.58	7.97	456.33	472.57	462.33	530.83	-521.38	-124.36
	160.56	86.45	130.77	356.97	48.60	3.59	108.30	118.09	122.10	1,769	71.80	55.95
	482.83	301.32	403.23	610.43	46.97	4.38	348.03	354.49	340.24	-1,214	-330.82	-63.55
	17.11	10.68	14.29	21.63	1.66	0.16	12.33	12.55	12.06	-44.04	-16.66	-7.11
Key metrics
	870.56	578.28	729.88	1,175	283.74	199.88	631.36	641.33	619.70	830.73	-239.97	138.55
	21.70%	15.30%	18.70%	19.40%	8.70%	6.10%	18.60%	18.70%	19.10%	27.10%	-9.60%	4.30%
	12.00%	8.00%	10.30%	10.10%	1.40%	0.10%	10.30%	10.30%	10.50%	-39.60%	-13.20%	-2.00%
	—	3.20%	—	8.60%	—	0.70%	—	—	—	—	—	—
	23.10%	15.80%	15.10%	76.10%	0.60%	6.30%	35.10%	7.10%	—	—	—	—
	928.00%	6,779.50%	15.90%	72.20%	-86.20%	100.40%	205.20%	657.80%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	17,737	16,983	13,322	11,813	12,990	12,305	10,944	10,641	9,865	9,103
	499.94	460.62	113.72	839.99	316.79	166.67	50.22	159.60	208.14	91.40
	13,761	13,192	11,663	11,716	11,673	10,769	9,656	9,737	8,940	8,075
	2,830	2,961	3,001	3,158	3,594	3,279	3,138	2,541	2,445	2,150
	2,476	2,397	1,566	1,451	1,268	1,118	750.27	1,029	976.30	754.75
	3,750	3,578	3,022	2,868	2,781	2,447	2,344	2,255	2,056	1,872
	204.49	208.72	207.06	515.97	349.58	298.10	353.11	377.32	334.58	285.57
	616.73	573.48	486.01	581.91	611.27	486.71	443.55	417.17	325.90	—
	4,212	4,085	3,595	3,336	3,394	3,152	2,817	2,989	2,861	2,577
	4,475	4,251	1,772	937.45	1,634	1,702	1,338	1,063	1,133	1,119
	-1,943	-2,266	-372.82	-900.96	-765.85	-260.91	44.55	32.88	167.18	0.00
	2,533	1,985	1,399	36.49	868.45	1,441	1,382	1,096	1,301	1,119
	734.75	622.79	352.07	1,867	491.05	447.60	412.39	320.11	375.64	315.46
	1,798	1,362	1,047	-1,434	377.40	993.65	970.09	775.97	924.99	803.87
	63.71	48.26	37.11	-67.30	10.53	33.37	34.38	27.50	32.78	—
Key metrics
	3,354	2,767	2,092	1,134	1,829	2,226	2,179	1,891	1,961	1,405
	18.91%	16.30%	15.70%	9.60%	14.10%	18.10%	19.90%	17.80%	19.90%	15.40%
	10.14%	8.00%	7.90%	-12.10%	2.90%	8.10%	8.90%	7.30%	9.40%	8.80%
	—	16.20%	15.90%	—	—	—	—	—	—	—
	—	27.50%	12.80%	-9.10%	5.60%	12.40%	2.80%	7.90%	8.40%	—
	—	30.10%	173.00%	-479.80%	-62.00%	2.40%	25.00%	-16.10%	15.10%	—
	—	2,087	-1,577	—	—	—	—	—	—	—
	—	2.53	-0.79	—	—	—	—	—	—	—
	—	0.00	0.25	—	—	—	—	—	—	—
	—	-1,175	518.48	—	—	—	—	—	—	—
	—	99.9	103.9	—	—	—	—	—	—	—
Balance sheet
	—	19,908	16,050	—	—	—	—	—	—	—
	—	11,300	9,295	—	—	—	—	—	—	—
	—	1,175	1,676	—	—	—	—	—	—	—
	—	4,963	3,342	—	—	—	—	—	—	—
	—	3,431	3,029	—	—	—	—	—	—	—
	—	1,505	—	—	—	—	—	—	—	—
	—	3,890	3,319	—	—	—	—	—	—	—
	—	3,744	2,580	—	—	—	—	—	—	—
	—	6,376	5,967	—	—	—	—	—	—	—
	—	0.00	2,194	—	—	—	—	—	—	—
	—	0.00	1,681	—	—	—	—	—	—	—
	—	0.00	512.70	—	—	—	—	—	—	—
	—	10,512	8,849	—	—	—	—	—	—	—
Cash flow
	—	3,445	-827.60	—	—	—	—	—	—	—
	—	-1,283	2.09	—	—	—	—	—	—	—
	—	-2,709	787.04	—	—	—	—	—	—	—
	—	1,358	749.57	—	—	—	—	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	2,435	2,147	2,360	1,539	2,395	2,009	2,251	2,636	2,330	2,148	1,365	2,233
	115.41	307.88	109.06	285.76	69.33	88.45	129.19	83.08	55.65	786.27	258.81	73.58
	1,907	2,193	1,945	1,799	1,740	1,738	1,821	1,924	1,767	1,787	1,674	1,898
	627.99	720.92	709.60	667.82	677.24	696.01	714.76	722.57	648.11	685.45	701.17	807.03
	141.44	113.50	104.66	91.31	99.33	91.48	89.09	103.65	88.98	81.66	77.72	81.23
	454.08	461.35	466.95	453.68	408.44	382.70	427.98	408.42	384.40	337.75	379.56	383.00
	23.25	17.91	21.98	23.40	15.46	13.13	8.46	11.79	15.35	83.39	73.60	58.19
	62.32	60.13	59.18	58.93	57.64	55.53	55.16	54.85	53.09	52.40	51.16	49.85
	549.08	820.21	526.26	606.70	540.17	500.15	544.48	614.96	520.01	548.04	474.85	512.59
	643.10	261.36	523.60	25.43	724.40	360.32	559.49	795.06	618.31	1,148	-50.22	409.04
	223.00	-368.76	-177.07	-931.79	-323.23	-179.17	—	—	—	5,147	-25.28	-19.67
	866.10	-107.40	346.53	-906.37	401.17	181.16	559.49	795.06	618.31	6,295	-75.50	389.37
	130.47	33.49	64.46	167.18	70.94	33.40	145.69	200.00	164.58	1,681	55.09	87.01
	735.64	-73.90	282.07	-739.19	330.23	147.76	413.80	595.06	453.73	4,614	-20.41	302.35
	26.07	-2.62	10.00	-26.19	11.70	5.24	14.66	21.09	16.08	163.50	-0.72	10.72
Key metrics
	951.67	-29.36	427.69	-824.04	474.27	249.82	623.11	861.70	686.75	6,431	49.26	497.41
	39.10%	-1.40%	18.10%	-53.60%	19.80%	12.40%	27.70%	32.70%	29.50%	299.30%	3.60%	22.30%
	30.20%	-3.40%	12.00%	-48.00%	13.80%	7.40%	18.40%	22.60%	19.50%	214.80%	-1.50%	13.50%
	—	-0.30%	—	-3.60%	—	0.80%	—	—	—	—	—	—
	1.70%	6.80%	4.80%	-41.60%	2.80%	-6.50%	64.90%	18.00%	—	—	—	—
	122.80%	-150.00%	-31.80%	-224.20%	-27.20%	-96.80%	2,127.40%	96.80%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18
Income statement
	8,480	8,440	9,226	7,891	8,221	8,142	7,568	6,713	6,305	6,432
	818.11	772.02	356.37	1,168	985.94	614.63	396.24	606.79	475.61	180.42
	7,845	7,677	7,250	7,129	7,139	6,849	6,094	5,803	5,307	5,393
	2,726	2,776	2,781	2,990	3,036	2,993	2,678	2,252	1,586	2,039
	450.91	408.80	373.21	322.78	391.19	481.62	315.95	365.24	301.30	288.18
	1,836	1,790	1,604	1,435	1,347	1,193	1,107	1,072	969.98	1,022
	86.54	78.75	48.73	277.11	206.82	236.04	265.90	256.39	223.81	190.90
	240.56	235.89	218.63	202.16	184.15	159.69	150.81	138.54	106.28	118.20
	2,502	2,493	2,180	2,005	2,006	1,802	1,571	1,670	1,648	1,684
	1,453	1,535	2,333	1,930	2,068	1,907	1,870	1,516	1,473	1,219
	-1,255	-1,801	-179.17	5,070	-495.87	430.33	73.89	18.55	345.19	—
	198.86	-266.07	2,154	7,001	1,572	2,337	1,944	1,535	1,818	1,219
	395.60	-65.27	543.67	1,833	363.11	339.66	294.31	180.10	329.88	204.48
	204.62	-200.80	1,610	5,167	1,209	1,998	1,649	1,355	1,622	1,014
	7.26	-7.12	57.07	183.13	42.84	70.80	58.46	48.00	52.75	—
Key metrics
	525.96	48.57	2,421	7,480	1,963	2,733	2,360	1,930	2,148	1,528
	6.20%	0.60%	26.20%	94.80%	23.90%	33.60%	31.20%	28.70%	34.10%	23.80%
	2.41%	-2.40%	17.50%	65.50%	14.70%	24.50%	21.80%	20.20%	25.70%	15.80%
	—	-0.70%	8.90%	—	—	—	—	—	—	—
	—	-8.50%	16.90%	-4.00%	1.00%	7.60%	12.70%	6.50%	-2.00%	—
	—	-112.50%	-68.80%	327.50%	-39.50%	21.10%	21.80%	-16.50%	59.90%	—
	—	543.30	247.85	—	—	—	—	—	—	—
	—	-2.71	0.37	—	—	—	—	—	—	—
	—	0.00	0.03	—	—	—	—	—	—	—
	—	-291.83	567.37	—	—	—	—	—	—	—
	—	79.9	71.1	—	—	—	—	—	—	—
Balance sheet
	—	29,485	28,033	—	—	—	—	—	—	—
	—	6,095	4,778	—	—	—	—	—	—	—
	—	291.83	131.45	—	—	—	—	—	—	—
	—	3,306	2,550	—	—	—	—	—	—	—
	—	1,288	1,369	—	—	—	—	—	—	—
	—	782.62	706.48	—	—	—	—	—	—	—
	—	1,748	1,661	—	—	—	—	—	—	—
	—	2,746	2,123	—	—	—	—	—	—	—
	—	3,669	3,246	—	—	—	—	—	—	—
	—	0.00	698.82	—	—	—	—	—	—	—
	—	0.00	698.82	—	—	—	—	—	—	—
	—	0.00	0.00	—	—	—	—	—	—	—
	—	24,150	24,504	—	—	—	—	—	—	—
Cash flow
	—	543.30	588.80	—	—	—	—	—	—	—
	—	569.23	-489.52	—	—	—	—	—	—	—
	—	-952.13	-95.41	—	—	—	—	—	—	—
	—	0.00	340.95	—	—	—	—	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +0.88%
Sales CAGR 5Y: +2.21%
Sales CAGR 10Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Profit CAGR 10Y: —
Sales YoY (TTM): -8.74%
Profit YoY (TTM): -86.24%

Consolidated

Sales CAGR 3Y: +9.34%
Sales CAGR 5Y: +9.19%
Sales CAGR 10Y: —
Profit CAGR 3Y: +53.39%
Profit CAGR 5Y: +7.02%
Profit CAGR 10Y: —
Sales YoY (TTM): +32.94%
Profit YoY (TTM): +138.48%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Jun 2026

Promoter holding: 46.65%

Holder	Type	Holding	Previous	Change
SALDANHA FAMILY TRUST	Promoter	45.44%	—	—
HDFC MUTUAL FUND - HDFC MID-CAP FUND	Public	6.22%	—	—
GOVERNMENT PENSION FUND GLOBAL	Public	3.89%	—	—
AMANSA HOLDINGS PRIVATE LIMITED	Public	2.22%	—	—
INVESCO INDIA CONTRA FUND	Public	2.20%	—	—
BANDHAN NIFTY 200 MOMENTUM 30 INDEX FUND	Public	1.28%	—	—
UTI MULTI CAP FUND	Public	1.15%	—	—
BLANCHE ELIZABETH SALDANHA	Promoter	0.39%	—	—
GLENN MARIO SALDANHA	Promoter	0.36%	—	—
CHERYLANN MARIA PINTO	Promoter	0.27%	—	—
ROBIN JOSEPH PINTO	Promoter Group	0.18%	—	—
NEHA SALDANHA	Promoter Group	0.01%	—	—

Public shareholders are disclosed individually only above 1%.

Filings & corporate actions

Recent announcements

Report of Scrutinizer is enclosed11 Sep 2026 · AGM/EGM / AGM
Proceedings of the 48th AGM of the Company is enclosed11 Sep 2026 · AGM/EGM / AGM
Glenmark expands Global Respiratory Innovation Footprint with RYALTRIS launch in Brazil11 Sep 2026 · Company Update / Press Release / Media Release
Please find enclosed rating rationale issued by India Ratings and Research11 Sep 2026 · Company Update / Credit Rating
Glenmark Pharmaceuticals Inc., USA launches Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy ....21 Aug 2026 · Company Update / Press Release / Media Release
Glenmark Pharmaceuticals receives U.S. FDA approval for Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray20 Aug 2026 · Company Update / Press Release / Media Release
Newspaper Advertisement regarding the 48th Annual General Meeting ("AGM") to be held on Friday, September 11, 2026 at 2.00 p.m. through Video Conferencing ("VC") / Other Audio-Visual Means ("OAVM")15 Aug 2026 · Company Update / Newspaper Publication
Letter to Shareholders whose email address are not registered providing the web link of Annual Report13 Aug 2026 · Company Update / General
Please find attached Business Responsibility and Sustainability Reporting for Financial Year 2025-2613 Aug 2026 · Others / Business Responsibility and Sustainability Reporting (BRSR)
Please find attached Notice convening the 48th Annual General Meeting and the Integrated Annual Report including BRSR for the Financial Year 2025-26.13 Aug 2026 · Others / Reg. 34 (1) Annual Report
Please find attached Notice of 48th Annual General Meeting for the Financial Year 2025-2613 Aug 2026 · AGM/EGM / AGM
Settlement Agreement - Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 201511 Aug 2026 · Company Update / General
Intimation of Allotment of shares under the Employee Stock Option Plan 201610 Aug 2026 · Company Update / Allotment of ESOP / ESPS
Intimation of Schedule of Analyst / Institutional Investor Meetings7 Aug 2026 · Company Update / Analyst / Investor Meet
Newspaper Advertisement regarding the 48th Annual General Meeting ("the AGM") to held through Video Conferencing ("VC")/ Other Audio-Visual Means ("OAVM")7 Aug 2026 · Company Update / Newspaper Publication
Transcript of the Earnings Call5 Aug 2026 · Company Update / Earnings Call Transcript
Audio recording of Q1 FY 2026-27 Earnings Call held on August 03, 20263 Aug 2026 · Company Update / Analyst / Investor Meet
The Unaudited (Standalone and Consolidated) Financial Results of the Company for the quarter ended June 30, 2026 have been published in Financial Express and Loksatta newspapers on Saturday, ....1 Aug 2026 · Company Update / Newspaper Publication
Investor Presentation - Q1 FY 26-2731 Jul 2026 · Company Update / Investor Presentation
Please find attached Press Release and Management Discussion & Analysis for the first quarter ended June 30, 202631 Jul 2026 · Company Update / Press Release / Media Release
Please find attached Company''s officials authorised for the purpose of determining materiality of an event or information and making disclosures to the Stock Exchanges31 Jul 2026 · Company Update / General
Intimation of Record Date for Dividend31 Jul 2026 · Corp. Action / Record Date
The Board of Directors has considered and approved the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 202631 Jul 2026 · Board Meeting / Outcome of Board Meeting
Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials28 Jul 2026 · Company Update / Press Release / Media Release
Newspaper advertisement for transfer of shares to IEPF Authority25 Jul 2026 · Company Update / Newspaper Publication
Intimation of Earnings Call21 Jul 2026 · Company Update / Analyst / Investor Meet
Glenmark receives U.S. FDA approval to expand the use of RYALTRIS Nasal Spray for Children aged 6 to less than 12 years21 Jul 2026 · Company Update / Press Release / Media Release
Glenmark Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/07/2026 ,inter alia, to consider and approve the Unaudited Financial ....15 Jul 2026 · Board Meeting / Board Meeting
Glenmark Pharmaceuticals Inc., USA launches Olanzapine for Injection, 10 mg/vial, Single - Dose Vial6 Jul 2026 · Company Update / Press Release / Media Release
Glenmark advances Multi-Country Phase 3 Clinical Trial of Trastuzmab rezetecan in Platinum-Resistant Ovarian Cancer2 Jul 2026 · Company Update / Press Release / Media Release
US FDA inspection at Company''s manufacturing facility in Goa, India30 Jun 2026 · Company Update / General
Intimation of schedule of analyst / institutional investor meeting25 Jun 2026 · Company Update / Analyst / Investor Meet
Intimation of Closure of Trading Window25 Jun 2026 · Insider Trading / SAST / Closure of Trading Window
Glenmark Pharmaceuticals Inc., USA launches Methylene Blue Injection USP, 50 mg/10mL (5 mg/mL) Single-Dose vial17 Jun 2026 · Company Update / Press Release / Media Release
Glenmark launches Winlevi (clascoterone) 10 mg/g cream in Key European Markets for the Treatment of Acne Vulgaris11 Jun 2026 · Company Update / Press Release / Media Release
Please find attached Investor Presentation to be made at Glenmark Pharmaceuticals Limited Investor Day 2026 today.9 Jun 2026 · Company Update / Investor Presentation
Transcript of the Earnings call has been uploaded on Company''s website5 Jun 2026 · Company Update / Earnings Call Transcript
Glenmark Pharmaceuticals Inc., USA launches Lacosamide Injection USP, 200 mg/ 20mL (10 mg/mL), Single-Dose Vials5 Jun 2026 · Company Update / Press Release / Media Release
We have uploaded Audio Recording of Q4 FY 2025-26 Earnings Call held on June 01, 2026 on the website of the Company.1 Jun 2026 · Company Update / Analyst / Investor Meet
Investor Presentation - Q4 FY 25-2629 May 2026 · Company Update / Investor Presentation

Corporate actions

Purpose	Ex date	Record date	Payment date
Final Dividend - Rs. - 2.5000	31 Aug 2026	31 Aug 2026	—
Interim Dividend - Rs. - 2.5000	3 Oct 2025	3 Oct 2025	—
Final Dividend - Rs. - 2.5000	15 Sep 2025	15 Sep 2025	—
Final Dividend - Rs. - 2.5000	13 Sep 2024	—	—

Board meetings

31 Jul 2026 Board Meeting - Financial Results